Nachrichten zur Intercept Pharmaceuticals Aktie

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc.…

ICPT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Intercept Pharmaceuticals, Inc. Is Fair to Shareholders

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating…

ICPT Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Intercept Pharmaceuticals to Alfasigma

MONSEY, N.Y., Sept. 26, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating…

Alfasigma to acquire Intercept Pharmaceuticals for $19 per share By Investing.com

Alfasigma to acquire Intercept Pharmaceuticals for $19 per share…

: Intercept Pharmaceuticals’ stock set to soar after Alfasigma buyout deal for an 82% premium

Shares of Intercept Pharmaceuticals Inc. ICPT were set to soar Tuesday, after the biopharmaceutical company announced an agreement to be…

Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases

BOLOGNA, Italy and MORRISTOWN, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A (“Alfasigma”), one of Italys leading…

Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Tops Revenue Estimates

Intercept (ICPT) delivered earnings and revenue surprises of 75% and 6.35%, respectively, for the quarter ended June 2023. Do the…

Intercept Pharma beats Q2 top and bottom line estimates; updates FY23 outlook

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates

MORRISTOWN, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on…

Intercept Pharma Q2 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intercept Pharma gains on H.C. Wainwright double upgrade

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intercept to reduce work force by one third as it aims for profitability

Intercept Pharmaceuticals Inc. ICPT on Friday said it will reduce its work force by one third as part of its…

Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses

MORRISTOWN, N.J., June 23, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced a restructuring to…

Intercept Pharmaceuticals to end NASH program following FDA feedback

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intercept Pharma Discontinues NASH-Related Investment, Will Focus on Liver Diseases

Intercept Pharma Discontinues NASH-Related Investment, Will Focus on Liver Diseases...…

Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

MORRISTOWN, N.J., June 22, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on…

Intercept (ICPT) Announces Positive Data From PBC Study

Intercept Pharmaceuticals (ICPT) announces new data showing the potential of a fixed-dose combination of OCA and bezafibrate to normalize multiple…

Intercept Pharmaceuticals stock price target cut to $15 from $30 at B. Riley

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

UPDATE 1-Intercept tumbles on concerns over prospects of fatty liver disease drug

...) By Leroy Leo May 22 (Reuters) - Shares of Intercept Pharmaceuticals......…

XFRA : I4P: Wiederaufnahme/Resumption

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…

Intercept Pharmaceuticals stock tumbles toward 11-month low after disappointing FDA committee vote

Shares of Intercept Pharmaceuticals Inc. ICPT tumbled 15.2% toward an 11-month low in premarket trading Monday, after the biopharmaceutical company…

XFRA : I4P: Aussetzung/Suspension

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME …

XFRA : INSTRUMENT_SUSPENSION - US45845P1084

Instrument ID [8735] (I4P - US45845P1084) suspended...…

Intercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on…

Intercept Pharmaceuticals gets ODD for fixed dose of OCA-bezafibrate to treat PBC

OCA is a farnesoid X receptor (FXR) agonist, which is marketed as Ocaliva by Intercept in the US to treat…

Intercept Pharmaceuticals Gets Orphan Drug Status for OCA and Bezafibrate to Treat Primary Biliary Cholangitis

Intercept Pharmaceuticals Gets Orphan Drug Status for OCA and Bezafibrate to Treat Primary Biliary Cholangitis...…

Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)

Company on track to complete planned interim analyses from two ongoing Phase 2 studies of the OCA-bezafibrate combination in 2023...…

Why Intercept Pharmaceuticals Stock Plunged Today

A modest revenue miss sparked a sell-off in the liver disease companys shares today....…

Intercept Pharma off 11% on Q1 misses

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intercept Pharma GAAP EPS of -$0.77 misses by $0.15, revenue of $68M misses by $4.68M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH

Ocaliva® net sales of $68.0 million, representing 15% growth over the prior year quarter...…

Nachrichten zur Intercept Pharmaceuticals Aktie

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

ICPT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Intercept Pharmaceuticals, Inc. Is Fair to Shareholders

ICPT Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Intercept Pharmaceuticals to Alfasigma

Alfasigma to acquire Intercept Pharmaceuticals for $19 per share By Investing.com

: Intercept Pharmaceuticals’ stock set to soar after Alfasigma buyout deal for an 82% premium

Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases

Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Tops Revenue Estimates

Intercept Pharma beats Q2 top and bottom line estimates; updates FY23 outlook

Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates

Intercept Pharma Q2 2023 Earnings Preview

Intercept Pharma gains on H.C. Wainwright double upgrade

Intercept to reduce work force by one third as it aims for profitability

Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses

Intercept Pharmaceuticals to end NASH program following FDA feedback

Intercept Pharma Discontinues NASH-Related Investment, Will Focus on Liver Diseases

Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

Intercept (ICPT) Announces Positive Data From PBC Study

Intercept Pharmaceuticals stock price target cut to $15 from $30 at B. Riley

UPDATE 1-Intercept tumbles on concerns over prospects of fatty liver disease drug

XFRA : I4P: Wiederaufnahme/Resumption

Intercept Pharmaceuticals stock tumbles toward 11-month low after disappointing FDA committee vote

XFRA : I4P: Aussetzung/Suspension

XFRA : INSTRUMENT_SUSPENSION - US45845P1084

Intercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

Intercept Pharmaceuticals gets ODD for fixed dose of OCA-bezafibrate to treat PBC

Intercept Pharmaceuticals Gets Orphan Drug Status for OCA and Bezafibrate to Treat Primary Biliary Cholangitis

Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)

Why Intercept Pharmaceuticals Stock Plunged Today

Intercept Pharma off 11% on Q1 misses

Intercept Pharma GAAP EPS of -$0.77 misses by $0.15, revenue of $68M misses by $4.68M

Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH

Intercept Pharma Q1 2023 Earnings Preview

7 Analysts Have This to Say About Intercept Pharma

Intercept Pharmaceuticals (ICPT) Reports Q4 Loss, Tops Revenue Estimates

Intercept Pharma GAAP EPS of -$0.50 misses by $0.26, revenue of $77.22M misses by $0.86M

Intercept Pharma Q4 2022 Earnings Preview

Intercept Pharma settles with Apotex over Ocaliva patents

Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Intercept Pharma gains after patent settlement with Amneal

dpa-AFX ProFeed